{
    "nctId": "NCT00044291",
    "briefTitle": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Neoplasms, Hormone-dependent",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 865,
    "primaryOutcomeMeasure": "Time to tumor progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women age 18 years or older\n* Pathological or histological confirmation of breast cancer at initial diagnosis or at the time of metastases\n* ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher\n* Predicted life expectancy of 12 weeks or more\n* Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago\n* Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease\n* At least one tumor localization measurable in 2 dimensions (one diameter at least 2 cm for soft tissue/visceral disease assessed by CT/MRI scan or conventional X-ray technique, one diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques)\n* Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional standard) at the time of initial diagnosis or determined during subsequent biopsy/surgery of metastases\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Prior hormonal therapy to treat locally recurrent, locally advanced or metastatic disease\n* Prior adjuvant therapy with aromatase inhibitors or antiestrogens/SERMs within 12 months prior to enrollment\n* Progression of disease during therapy with antiestrogens (including SERMs administered for prevention of osteoporosis)\n* Life-threatening locally recurrent, locally advanced or metastatic disease or disease requiring chemotherapeutic intervention (such as inflammatory breast cancer)\n* History of known CNS metastases, significant neurological dysfunction including active seizures, or clinical signs of other significant neurological diseases\n* Other active malignancy (except basal cell carcinoma of the skin or in situ cervical cancer). Patients with previous malignancies must be without evidence of disease for at least five years\n* Renal insufficiency (serum creatinine \\> 2.0 mg/dL)\n* Aspartate aminotransferase, alanine aminotransferase or serum bilirubin levels more than 2.5 times upper limit of normal\n* Hemoglobin \\<9 g/dL\n* Platelet count of less than 100,000 platelets per mm3\n* Total white blood cell count of less than 2,000 cells per mm3\n* Premenopausal endocrine status; pregnant or lactating females\n* Usage of an investigational drug within the thirty (30) days prior to enrollment; or the planned usage of an investigational drug other than the study medication during the course of the current study\n* Contraindication to use of toremifene, atamestane, letrozole or any of the inactive components of their formulations\n* Prior enrollment in this study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}